Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.

Chimeric antigen receptor T-cell (CAR-T) therapies such as axicabtagene ciloleucel (axi-cel), and brexucabtagene autoleucel (brexu-cel) are approved by the United States Federal Drug Administration for relapsed or refractory large B-cell lymphoma (LBCL), follicular lymphoma and mantle cell lymphoma (MCL).1-5 Given the risk of significant toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the registrational trials for axi-cel and brexu-cel required hospitalisation for close monitoring. Patients received lymphodepleting chemotherapy and CAR-T infusion in the outpatient clinic and were subsequently monitored with twice daily in-person visits and one overnight remote visit via telemedicine through day 14 post-infusion. Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. [Extracted from the article]